Areas of Interest & Competitive Research Grants

Areas of Interest (AOI)

We are currently accepting concepts for the following therapeutic areas. BMS periodically opens RFP Cycles across different therapeutic areas and the pre-concept submission periods will be posted below when available. We strongly encourage all applicants to begin the online application process early to allow adequate time for completion. For a submission to qualify for review, all information including any required uploads must be submitted through the application form prior to the specified end dates for the RFP Cycle.

Therapeutic Area and / or Compound AOIs Posted on BMS.com Pre-Concept Submission Period
Start Date End date
CV-Mavacamten -2023_RFP_Cycle_1 18-May-23 30-May-23 20-Jul-23
Immunology – Zeposia UC (Ozanimod) 20-Mar-23 08-May-23 25-May-23
Immunology – Zeposia MS (Ozanimod) 30-Jun-23 10-Jul-23 27-Jul-23


CV-Mavacamten - 2023_RFP_Cycle_1

 

Obstructive HCM diagnosis and management
In Scope: 

  • Earlier diagnostic approach to the at-risk population
  • Diagnosis and monitoring of HCM progression
  • Monitoring may include:
    • Biomarkers, imaging, and correlation with clinical and trial endpoints.

*Interventional and observational projects are acceptable, including new approaches to real-world data.


Out of Scope:

Off-label (non-obstructive HCM, etc.); head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; re-analysis of clinical trial data.


The Impact of CAMZYOS on Pathophysiology and disease progression

In Scope: 

  • Special interest in the following: 
    • Arrhythmias (Atrial & Ventricular) 
    • Cardiac structure (strain, energetics, etc.)
    • Additional complications from the disease

*Interventional and observational projects are acceptable, including new approaches to real-world data.


Out of Scope:

Off-label (non-obstructive HCM, etc.); head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; re-analysis of clinical trial data.


CAMZYOS echo monitoring. 

In Scope: 

  • Assess the benefits of innovative Echo technology in diagnosis, monitoring, workflow, access, coordination of care, and health equity in correlation with CAMZYOS label

*Interventional and observational projects are acceptable, including new approaches to real-world data.


Out of Scope:

Off-label (non-obstructive HCM, etc.); head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; re-analysis of clinical trial data.


Clinical use of CAMZYOS

In Scope: 

  • In special populations (minorities, elderly, comorbidities)
  • CAMZYOS use in patients with milder symptoms (within the label-indicated population)
  • Impact on reduced/ delayed need for surgery
  • Impact on the quality of life
  • Adjustment of background therapy (beta-blockers, calcium-channel blockers, ARBs)

*Interventional and observational projects are acceptable, including new approaches to real-world data.


Out of Scope:

Off-label (non-obstructive HCM, etc.); head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; re-analysis of clinical trial data.


Implementation of best practices

In Scope: 

  • Decision-making support to include patient-preference
  • Approaches to improve patient and provider experience with CAMZYOS

*Interventional and observational projects are acceptable, including new approaches to real-world data.


Out of Scope:

Off-label (non-obstructive HCM, etc.); head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; re-analysis of clinical trial data.


Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.

  • If you are a potential investigator who is interested in seeking support to conduct independent research involving  Nivolumab  in Japan, Taiwan, or Korea, click here
  • If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
  • If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
  • If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here

Please click on the product name to see the Full U.S. Prescribing Information for ELIQUIS®, EMPLICITI, NULOJIX®, OPDIVO®, ORENCIA®, SPRYCEL®, YERVOY®, including Boxed WARNINGS for ELIQUIS®, NULOJIX®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions.

Begin a New Application